Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
Interventions: Trametinib, Dabrafenib, PDR001; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Medically-tailored meal delivery and medical nutrition therapy; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Sitagliptin; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery; Biological · Drug · Other + 1 more
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more

Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 25
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more

Conditions: Neoplasms, Pancreatic
Interventions: GSK3145095, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 588 participants
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
Interventions: LASN01, Placebo; Drug
Lead sponsor: Lassen Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Polycystic Ovary Syndrome
Interventions: Nutrition Education, Dietary Counseling, and Cooking; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Retinopathy
Interventions: Octreotide Acetate in Microspheres, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetic Neuropathy
Interventions: Centella asiatica selected triterpenes (CAST), Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type II Diabetes Mellitus
Interventions: JTT-130, JTT-130 Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 48
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Scottsboro, Alabama + 45 more

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: Lifestyle Modification; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 12 Years and older
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Hypogonadism, Male
Interventions: SOV2012-F1, AndroGel; Drug
Lead sponsor: Marius Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 31 more

Conditions: Epithelial Ovarian Cancer
Interventions: Seprafilm™; Procedure
Lead sponsor: University of British Columbia; Other
Eligibility: Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Mellitus, Type 2
Interventions: Digital health Partnership program; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Graves Disease, Hyperthyroidism/Thyrotoxicosis
Interventions: Heart rate-based AI software for detecting thyrotoxicosis; Device
Lead sponsor: THYROSCOPE INC.; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Prostate Adenocarcinoma
Interventions: Radiation therapy; Radiation
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms
Interventions: Not listed
Lead sponsor: The Canadian College of Naturopathic Medicine; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 7
States / cities: Scottsdale, Arizona • Kailua, Hawaii • Fife, Washington + 2 more

Conditions: Diabetes
Interventions: Community Health worker; Other
Lead sponsor: Columbia University; Other
Eligibility: 35 Years to 70 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 14
States / cities: Cypress, California • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Human Immunodeficiency Virus (HIV), Sexually Transmitted Disease (STD)
Interventions: STAND HIV Risk Reduction Intervention, Text Messaging Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 391 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Group Visits; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Food and Education Effects on Diabetes Study

Sitagliptin in Combination With Metformin and Sulfonylurea

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

A Cooking and Eating Study

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Peru Longitudinal Study

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c

Evaluating an AI Tool for Detecting Thyrotoxic States

Islet Transplantation for Type 1 Diabetes

Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

The Canadian/US Integrative Oncology Study

Northern Manhattan Diabetes Community Outreach Project

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

Efficacy Study of Diabetes Group Visits